Skip to main content

Alveolar Soft Part Sarcoma

  • Chapter
  • First Online:
Management of Soft Tissue Sarcoma

Abstract

Alveolar soft part sarcoma (ASPS) is a rare sarcoma that typically arises in the lower extremity in adolescents and young adults between 15 and 40 years of age. Distribution by age and site in adults is shown in Figs. 17.1 and 17.2 for all adult ASPS. In children, a number of cases arise from the tongue and orbit, where it can be confused to some degree with embryonal rhabdomyosarcoma. ASPS is extremely rare, even at referral centers, which have been hard pressed to identify more than one to two patients a year per center in published series [1–3]. It frequently presents with innumerable small, round metastatic lesions in the lungs and shows a very slow rate of progression, one reason for the late presentation of what is often a primary >10 cm in greatest dimension. Progression is typically slow, but ultimately taking the patient’s life after 10–15 years of metastatic disease. Brain metastases are a particular feature of ASPS, with an incidence at least thrice of that of other sarcomas in one series and documentation in other series [4–7].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lieberman PH, Brennan MF, Kimmel M, et al. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer. 1989;63(1):1–13.

    Article  PubMed  CAS  Google Scholar 

  2. Pennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010:17(12):3229–33.

    Google Scholar 

  3. Kayton ML, Meyers P, Wexler LH, et al. Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg. 2006;41(1):187–93.

    Article  PubMed  Google Scholar 

  4. Haga Y, Kusaka G, Mori S, et al. A case of alveolar soft-part sarcoma with cerebral metastases. No To Shinkei. 1996;48(3):269–74.

    PubMed  CAS  Google Scholar 

  5. Postovsky S, Ash S, Ramu IN, et al. Central nervous system involvement in children with sarcoma. Oncology. 2003;65(2):118–24.

    Article  PubMed  CAS  Google Scholar 

  6. Reichardt P, Lindner T, Pink D, et al. Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer. 2003;39(11):1511–6.

    Article  PubMed  CAS  Google Scholar 

  7. Pennacchioli E, Fiore M, Collini P, et al. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. Ann Surg Oncol. 2010;17(12):3229–33.

    Article  PubMed  Google Scholar 

  8. Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48–57.

    Article  PubMed  CAS  Google Scholar 

  9. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179–92.

    Article  PubMed  CAS  Google Scholar 

  10. Ladanyi M, Antonescu CR, Drobnjak M, et al. The precrystalline cytoplasmic granules of alveolar soft part sarcoma contain monocarboxylate transporter 1 and CD147. Am J Pathol. 2002;160(4):1215–21.

    Article  PubMed  CAS  Google Scholar 

  11. Kuriyama K, Todo S, Hibi S, et al. Alveolar soft part sarcoma with lung metastases. Response to interferon alpha-2a? Med Pediatr Oncol. 2001;37(5):482–3.

    Article  PubMed  CAS  Google Scholar 

  12. Bisogno G, Rosolen A, Carli M. Interferon alpha for alveolar soft part sarcoma. Pediatr Blood Cancer. 2005;44(7):687–8.

    Article  PubMed  Google Scholar 

  13. Gardner K, Leahy M, Alvarez-Gutierrez M, et al. Activity of the VEGFR/KIT tyrosine kinase inhibitor cediranib (AZD2171) in alveolar soft part sarcoma. Proc Connect Tissue Oncol Soc (www.ctos.org). 2008;14:Abstr 34936

  14. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15(3):1096–104.

    Article  PubMed  CAS  Google Scholar 

  15. Rekhi B, Ingle A, Agarwal M, et al. Alveolar soft part sarcoma ‘revisited’: clinicopathological review of 47 cases from a tertiary cancer referral centre, including immunohistochemical expression of TFE3 in 22 cases and 21 other tumours. Pathology. 2012;44(1):11–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Maki, R.G. (2013). Alveolar Soft Part Sarcoma. In: Management of Soft Tissue Sarcoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5004-7_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5004-7_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5003-0

  • Online ISBN: 978-1-4614-5004-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics